DOCSLIB.ORG

Washington State 2020 Annual Report (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Washington State 2020 Annual Report (PDF) First MED-Project Annual Report For 2019 Operating Period State of Washington Due July 1, 2020 Prepared By: MED-Project WA, LLC Submitted To: Washington State Department of Health Table of Contents I. Executive Summary ............................................................................................................... 3 II. Annual Budget ...................................................................................................................... 3 Table 1: Annual Budget .................................................................................................................. 4 Appendix A ................................................................................................................................ 5 List of Covered Manufacturers ......................................................................................................... 5 Table 2: List of Covered Manufacturers.......................................................................................... 21 2 I. Executive Summary MED-Project WA, LLC’s (“MED-Project”) Product Stewardship Plan for Covered Drugs from Households (“Plan”) was approved by the Washington State Department of Health (the "Department") on May 25, 2020. Per the Plan, MED-Project will initiate operations by November 21, 2020, which is within 180 days of the Plan approval date. This first Annual Report for the 2019 reporting period was requested by the Department and includes an update to the annual budget that occurred after the submission of the proposed Plan and a list of Covered Manufacturers participating as of May 2020. No operational information for the Department is available to report for the 2019 calendar year because the MED-Project operations start date is November 21, 2020. II. Annual Budget MED-Project has developed a budget based on the assumptions covered in Section XI of the Plan. The Program budget for total cash expenditures includes forecasts, projections, and other predictive statements that represent MED-Project’s assumptions and expectations in light of currently available information. This program budget is based on MED-Project’s current knowledge of performance, industry trends, and other factors, and involves risks, variables, and uncertainties. MED-Project’s actual performance results may differ from those projected in the program budget. No guarantee is implied as to the accuracy of the program budget. MED-Project updated the annual budget based on modifications made during the proposed plan review process with the Department. As a result, MED-Project is projecting an increased budget estimate from the annual budget submitted in the approved Plan. In accordance with RCW 69.48.090(1) and WAC 246-480-040(5)(a-c), MED-Project’s budget is summarized in Table 1: 3 Annual Budget COST AMOUNT1 Administrative Costs2 $1,456,000 Collection and Disposal Costs3 $2,237,000 Communication Costs4 $541,000 Total Program Costs $4,234,000 Table 1: Annual Budget 1 The Program start is Q2 2020. The budget covers a 12-month calendar period of anticipated program implementation and operations from June 2020 through May 2021 (Note: Budget estimate does not include the Program Operator initial fee in 2019 payable to the Department). 2 Administrative Costs take into account: − Contracted and employed personnel overhead costs. − Legal fees. − Local and state business licensing fees. − Local, state, and federal taxes. − Property costs, including rentals. − Utilities, phone, and internet. − General equipment and supplies. 3 Collection and Disposal Costs take into account: − Collection, transportation, and disposal of drugs. − Purchase, maintenance, and replacement of collection receptacles. − Compensation of authorized collectors, if separate from personnel costs covered in the Administrative Costs above. − Contracted and employed personnel costs associated with collection and disposal. − Production, distribution, and postage of mailers. 4 Communication Costs take into account: − Advertising. − Marketing. − Contracted and employed personnel costs associated with communication. − Website creation and maintenance. − Operation of a toll-free call center. 4 Appendix A List of Covered Manufacturers A list of the Covered Manufacturers participating in the Product Stewardship Program during the Reporting Period. PARENT COMPANY COMPANY NAME 3M Corporation 3M Corporation 3M Corporation 3M Drug Delivery Systems 3M Corporation 3M ESPE 3M Corporation 3M Health Care 3M Corporation 3M Personal Care AbbVie Inc. AbbVie Inc. AbbVie Inc. Pharmacyclics, subsidiary of AbbVie Inc. ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Accord Healthcare Inc. Accord Healthcare Inc. Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. Acorda Therapeutics, Inc. Acorda Therapeutics, Inc. Acorda Therapeutics, Inc. Acorda Therapeutics, Inc. Acorda Therapeutics, Inc. Civitas Therapeutics, Inc. Adapt Pharma Inc. Adapt Pharma Inc. Advantice Health Advantice Health Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceuticals, Inc. Afaxys Inc. Afaxys Inc. Ajanta Pharma USA Inc. Ajanta Pharma USA Inc. AkaRx, Inc., dba Dova Pharmaceuticals AkaRx, Inc., dba Dova Pharmaceuticals Akebia Therapeutics, Inc. Akebia Therapeutics, Inc. Akorn, Inc. Akorn, Inc. Akorn, Inc. Advanced Vision Research Inc. d.b.a. Akorn Consumer Health Akorn, Inc. Akorn Animal Health, Inc. Akorn, Inc. Clover Pharmaceuticals Corp. Akorn, Inc. Hi-Tech Pharmacal Co., Inc. 5 PARENT COMPANY COMPANY NAME Akorn, Inc. Inspire Pharmaceuticals, Inc. Akorn, Inc. Oak Pharmaceuticals, Inc. Akorn, Inc. Olta Pharmaceuticals Corp. Akorn, Inc. Versapharm, Incorporated AKRON COATING & ADHESIVES AKRON COATING & ADHESIVES Alembic Pharmaceuticals Inc. Alembic Pharmaceuticals Inc. Allergan, Inc. Allergan, Inc. Allergan, Inc. Actavis Pharma, Inc. (only for labeler code 52544) Allergan, Inc. Allergan Sales, LLC Allergan, Inc. Allergan USA, Inc. Allergan, Inc. Aptalis Pharma US, Inc. Allergan, Inc. Durata Therapeutics US Limited Allergan, Inc. Forest Laboratories, LLC Allergan, Inc. Pacific Pharma, Inc. Allergan, Inc. Warner Chilcott (US), LLC Allergan, Inc. Watson Laboratories, Inc. (only for labeler code 52544) Almirall LLC Almirall LLC Alva-Amco Pharmacal Companies, Inc. Alva-Amco Pharmacal Companies, Inc. Alvogen Pharma US, Inc. Alvogen Pharma US, Inc. Alvogen Pharma US, Inc. Almaject, Inc. Alvogen Pharma US, Inc. Almatica Pharma, Inc. Alvogen Pharma US, Inc. Alvogen, Inc. Alvogen Pharma US, Inc. County Line Pharmaceuticals LLC Alvogen Pharma US, Inc. Norwich Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. AMAG Pharma USA, Inc. Amarin Pharma, Inc. Amarin Pharma, Inc. Amarin Pharma, Inc. Amarin Corp. PLC Amarin Pharma, Inc. Amarin Pharma Inc. 6 PARENT COMPANY COMPANY NAME Amarin Pharma, Inc. Amarin Pharmaceuticals Ireland Ltd. Amerigen Pharmaceuticals, Inc. Amerigen Pharmaceuticals, Inc. Amerigen Pharmaceuticals, Inc. Amerigen Pharmaceuticals, Inc. Amgen Inc. Amgen Inc. Amgen Inc. Amgen USA Amgen Inc. Immunex Corporation Amgen Inc. Onyx Pharmaceuticals Amici Pharmaceuticals LLC Amici Pharmaceuticals LLC Amneal Pharmaceuticals LLC Amneal Pharmaceuticals LLC Amneal Pharmaceuticals LLC Amedra Laboratories LLC Amneal Pharmaceuticals LLC CorePharma, LLC Amneal Pharmaceuticals LLC Gemini Laboratories, LLC Amneal Pharmaceuticals LLC Impax Laboratories, Inc. Amneal Pharmaceuticals LLC Lineage Therapeutics Inc. Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. Armstrong Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. International Medication Systems, LTD Amring Pharmaceuticals Inc. Amring Pharmaceuticals Inc. ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. Apotex Holdings, Inc. Apotex Holdings, Inc. Apotex Holdings, Inc. ApoPharma USA, Inc. Apotex Holdings, Inc. Apotex Corp. Apotex Holdings, Inc. Aveva Drug Delivery Systems, Inc. Aprecia Pharmaceuticals, LLC Aprecia Pharmaceuticals, LLC Aptevo BioTherapeutics LLC Aptevo BioTherapeutics LLC Arbor Pharmaceuticals, Inc. Arbor Pharmaceuticals, Inc. Ascend Laboratories, LLC Ascend Laboratories, LLC Ascend Therapeutics US, LLC Ascend Therapeutics US, LLC Asclemed USA dba Enovachem Asclemed USA dba Enovachem Pharmaceuticals, Pharmaceuticals, Enovachem Enovachem Manufacturing Manufacturing 7 PARENT COMPANY COMPANY NAME Assertio Therapeutics, Inc. Assertio Therapeutics, Inc. Astellas Pharma US, Inc. Astellas Pharma US, Inc. AstraZeneca Pharmaceuticals LP AstraZeneca Pharmaceuticals LP AstraZeneca Pharmaceuticals LP AstraZeneca Pharmaceuticals LP Aubio Life Sciences Aubio Life Sciences Aurobindo Pharma USA, Inc Aurobindo Pharma USA, Inc Azurity Pharmaceuticals, Inc. Azurity Pharmaceuticals, Inc. Azurity Pharmaceuticals, Inc. Silvergate Pharmaceuticals, Inc. B.F. Ascher & Co., Inc. B.F. Ascher & Co., Inc. Bausch Health Companies Bausch Health Companies Bausch Health Companies Bausch + Lomb Bausch Health Companies Salix Baxter Healthcare Corporation Baxter Healthcare Corporation Bayer HealthCare LLC Bayer HealthCare LLC Bayer HealthCare LLC Bayer Consumer Care Holdings LLC Bayer HealthCare LLC Bayer HealthCare Animal Health Inc. Bayer HealthCare LLC Bayer HealthCare Pharmaceuticals Inc. Bayer HealthCare LLC Bayer HealthCare Pharmaceuticals LLC Bayer HealthCare LLC MSD Consumer Care Inc. BE Pharmaceuticals, Inc. BE Pharmaceuticals, Inc. BestCo, Inc. BestCo, Inc. Bimeda Inc. Bimeda Inc. Biocon Pharma, Inc. Biocon Pharma, Inc. Biogen Inc. Biogen Inc. BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical
Load more

Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
    [Show full text]
  • Pfizer's Bourla
    No. 3985 December 13, 2019 line success and business development. “In the next two years, we need to see how the pipeline is delivering,” he said. Bourla has been outspoken that when it comes to business development, he doesn’t see a mega-merger on the hori- zon. Instead, he said he is looking to bring in mid-stage clinical development assets to complement the internal pipeline. It sounds like investors can expect the company to be active on the business development front within those guard- rails. “I want to double it,” he said of the pipeline, which includes 92 projects right now. “And, we are going to double it by bringing in a lot of innovation to comple- ment what we distribute.” The company is focusing business de- velopment on six core therapeutic areas Pfizer’s Bourla: “I Think We Forgot as well, but Bourla indicated the company will be actively building out those areas both through internal investment and What It Looks Like To Grow” external collaboration. “We’re going to be JESSICA MERRILL [email protected] active because Pfizer is a very big plane and it cannot fly with one engine,” he said. fizer Inc. CEO Albert Bourla took in July it will merge the Upjohn business Bourla highlighted Pfizer’s recent acqui- over the top leadership spot from with Mylan NV to form a new generic drug sition of the cancer specialist Array Bio- PIan Read a year ago, but has quickly company to be called Viatris GMBH. Pharma for $11.4bn as an example of the executed on big changes poised to make The resulting Pfizer will be significantly kinds of deals the company will be pursu- Pfizer significantly smaller and faster smaller, with a 2020 annual revenue base ing.
    [Show full text]
  • Daiichi Sankyo Move Could Spark Copycats
    June 12, 2008 Daiichi Sankyo move could spark copycats Lisa Urquhart Daiichi Sankyo’s surprise move yesterday on Ranbaxy sparked not only a flurry of news about the $4.1bn deal, but has also got many in the market wondering who else might be on the shopping list of other big pharma companies looking to snap up an Indian generics firm. Those excited by the acquisition are pointing to the attractions of these companies, which include the increasing moves by governments to use generics to reduce healthcare costs, and in the case of Indian generic companies, their access to the fast growing, developing markets that big pharma has already expressed an interest in. With Ranbaxy now out of the picture, according to the EvaluatePharma’s Peer Group Analyzer Glenmark would be one of the most attractive in terms of future growth. The company may not be in the top three of the biggest Indian generics, but it is forecast to report an impressive 38% compound annual growth in unbranded generic sales in the five years to 2012. WW Unbranded Generic Sales WW annual sales ($m) CAGR (07-12) Market Rank 2007 2012 2007 2012 Glenmark Pharmaceuticals 244 1,211 38% 30 16 Wockhardt 357 764 16% 25 20 Lupin 303 647 16% 27 26 Aurobindo Pharma 165 334 15% 31 31 Matrix Laboratories 131 265 15% 34 35 Cipla 872 1,656 14% 14 11 Ranbaxy Laboratories 1,496 2,827 14% 9 6 Torrent Pharmaceuticals 300 543 13% 28 29 Piramal Healthcare 418 756 13% 20 21 Zydus Cadila 395 697 12% 22 24 Sun Pharmaceutical Industries 775 1,332 11% 15 15 Dr.
    [Show full text]
  • 1 Azbil Telstar Tecnologies S.L.U
    AZBIL TELSTAR TECHNOLOGIES, S.L.U. 1 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 AUDIT PLAN 2020 AZBIL TELSTAR TECNOLOGIES S.L.U Manufacturer Country Address AARTI INDUSTRIES LTD. India Unit IV - Plot No. E-50, MIDC, Tarapur, Tal-Palghar Dist. Thane, Maharashtra 401506 - India Commercial Hub road,Near APIIC Pump House,Plot No:2, Road No:21,J.N.Pharma City (Ramky),Tadi ACACIA LIFE SCIENCES Pvt. Ltd. (BIOCON) India Village, IDA Paravada,Visakhapatnam, India - 531 021 Unit-III Plot No. 842-843, Village-Karakhadi, Taluk-Padra, District-Panchmahal, Vadodara-391 450, ALEMBIC PHARMACEUTICALS LTD. India Gujarat, INDIA ALEMBIC PHARMACEUTICALS LTD. India Village Panelav, Near Baska. Taluka Halol, District Panchmahal - 389 350 Gujarat - India AMI LIFE SCIENCES PVT. LTD. India Block No 82/B, ECP Road, At & Post : Karakhadi-391 450 Ta: Padra, Dist. Baroda, Gujarat, INDIA. AMINO CHEMICALS (MOEHS) Malta MRA 050X, Industrial Estate. Marsa MRS 3000 Malta. AMINO CHEMICALS (MOEHS) Malta MRA 050X, Industrial Estate. Marsa MRS 3000 Malta. ANUGRAHA CHEMICALS India D-46-50 &C-62 & 63 KSSIDC Indl Estate Doddaballpura, Bangalore 561 203 INDIA Nº D47 to D50, C62 & C 63, KSSIDC Industrial State, Doddaballapur, Bangalore, Karnataka, 561203 ANUGRAHA CHEMICALS India INDIA ARCH UK BIOCIDES UK Wheldon Road, Castelford, West Yorkshire - WF 102JT, England Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 2 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 AURO LABORATORIES LIMITED India K-56, M.I.D.C. Tarapur, Boisar, Dist. Thane, Maharashtra – 401 506, INDIA AUROBINDO UNIT IX India Unit IX.
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • March 31, 2021
    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
    [Show full text]
  • Alembic Pharmaceuticals Limited
    Placement Document Not for Circulation and Strictly Confidential Serial Number: ___ ALEMBIC PHARMACEUTICALS LIMITED Registered and Corporate Office: Alembic Road, Vadodara 390 003, Gujarat, India Telephone: +91 265 228 0550; Fax: +91 265 228 2506 E-mail: [email protected]; Website: www.alembicpharmacueticals.com; CIN: L24230GJ2010PLC061123 Alembic Pharmaceuticals Limited (our “Company" or the “Issuer”) was originally incorporated on June 16, 2010 as “Alembic Pharma Limited”, a public limited company under the Companies Act, 1956. Thereafter, our Company commenced its business on July 1, 2010, pursuant to a certificate of commencement of business issued to it by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the name of our Company was changed to “Alembic Pharmaceuticals Limited”, pursuant to a fresh certificate of incorporation consequent upon change of name dated March 12, 2011, issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. For details with respect to changes to the name of our Company, see "General Information" on page 179. Our Company is issuing 80,47,210 Equity Shares (as defined below) at a price of ₹932.00 per Equity Share (the “Issue Price”), including a premium of ₹930.00 per Equity Share, aggregating to approximately ₹750.00 crore (the “Issue”). For further details, see “Summary of the Issue” on page 29. THIS ISSUE IS BEING UNDERTAKEN IN RELIANCE UPON CHAPTER VI OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI REGULATIONS”) AND SECTION 42 OF THE COMPANIES ACT, 2013 AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (“COMPANIES ACT”) The equity shares of our Company, of face value of ₹ 2 each (the “Equity Shares”) are listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”, and together with BSE, the “Stock Exchanges”).
    [Show full text]
  • Health Industry Business Communications Council
    Health Industry Business Communications Council Registered Labelers: Accredited Auto-ID Labeling Standards Argentina New MedTek Devices Pty Ltd Oxavita SRL Norseld Pty Ltd. Novadien Healthcare Pty Ltd The following companies Odontit S.A. (and/or their subsidiaries/ PAMPAMED S.R.L. Numedico Technologies Pty Ltd divisions) have applied PATEJIM SRL Opto Global Pty. Ltd. for a Labeler Identification Orthocell Limited Code (LIC) assignment with Austria Prolotus Technologies Pty Ltd HIBCC*. By doing so, they afreeze GmbH Red Milawa Pty Ltd dba Magic Mobility have demonstrated their AMI GmbH SDI Limited commitment to patient safety Bender Medsystems GmbH Signostics Ltd. and logistical efficiency for BHS Technologies GmbH Sirtex Medical Pty Ltd their customers, the industry Metasys Medizintechnik GmbH Smith & Nephew Surgical Pty. Ltd. and the public at large. PAA Laboratories GmbH Staminalift International Limited Safersonic Medizinprodukte Handels The Pipette Company Pty. Ltd. Any organization that is GmbH Thermo Electron Corporation interested in using the HIBC W & H Dentalwerk Burmoos GmbH Vush Pty Ltd uniform labeling system may apply for the assignment of VUSH STIMULATION Australia one or more LICs. William A Cook Australia Pty. Ltd. Adv. Surgical Design & Manufacture, Ltd. Last updated 9-21-2021 AirPhysio Pty Ltd Belgium Annalise-AI Pty Ltd 3M Europe Apollo Medical Imaging Technology Pty Advanced Medical Diagnostics SA/NV Ltd Analis SA/NV Benra Pty Ltd dba Gelflex Laboratories Baxter World Trade Bioclone Australia Pty. Ltd. Bio-Rad RSL Candelis, Inc. Bio-Rad Lab Inc Clinical Diag. Group DePuy Australia Pty. Ltd. Biosource Europe SA For more information, please dorsaVi Ltd Cilag NV contact the HIBCC office at: EC Certification Service GmbH Coris Bioconcept Fink Engineering Pty Ltd Fuji Hunt Photographic Chemicals NV 2525 E.
    [Show full text]
  • Inner 11 Equity PE Fund
    Modera erate tely Mod High to H w te ig o ra h L de o M V e r y w H Tata Equity P/E Fund o i L g (An open ended equity scheme following a value investment strategy) h Riskometer Investors understand that their principal As on 31st May 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily invests at least 70% of the net assets in equity Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets shares whose rolling P/E ratio on past four quarter earnings Equity & Equity Related Total 458548.17 97.42 Leisure Services for individual companies is less than rolling P/E of the S&P Auto Jubilant Foodworks Ltd. 167000 5195.70 1.10 BSE SENSEX stocks. Bajaj Auto Ltd. 250800 10515.54 2.23 Minerals/Mining INVESTMENT OBJECTIVE Tata Motors Ltd. 3000000 9562.50 2.03 NMDC Ltd. 2600000 4735.90 1.01 The investment objective of the Scheme is to provide Escorts Ltd. 475484 5571.72 1.18 Pesticides reasonable and regular income and/or possible capital appreciation to its Unitholder. However, there is no Auto Ancillaries Rallis India Ltd. 2250000 7048.13 1.50 assurance or guarantee that the investment objective of the MRF Ltd. 10600 8865.99 1.88 Petroleum Products Scheme will be achieved. The scheme does not assure or Ceat Ltd. 308700 4081.01 0.87 Reliance Industries Ltd. 1715000 37049.15 7.87 guarantee any returns. Banks Pharmaceuticals DATE OF ALLOTMENT ICICI Bank Ltd.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • ANNUAL REPORT 2018-19 2 Notice
    CONTENTS Corporate Information ............................................................................................................ 02 Notice .................................................................................................................................... 03 Directors’ Report .................................................................................................................... 14 Annexures to Directors’ Report .............................................................................................. 25 Management Discussion and Analysis .................................................................................. 53 Business Responsibility Report ............................................................................................. 69 Report on Corporate Governance ......................................................................................... 80 Standalone Financial Statements .......................................................................................... 99 Consolidated Financial Statements ....................................................................................... 154 Financial Highlights - 5 years ................................................................................................. 212 CORPORATE INFORMATION BOARD OF DIRECTORS STATUTORY AUDITORS 1. Shri Sudhir Mehta B S R & Co. LLP Chairman Emeritus Chartered Accountants 2. Shri Samir Mehta Executive Chairman REGISTERED OFFICE 3. Shri Shailesh Haribhakti Torrent House, 4. Shri Haigreve
    [Show full text]
  • Annual Return
    FORM NO. MGT-7 Annual Return [Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of (other than OPCs and Small rule 11of the Companies (Management and Companies) Administration) Rules, 2014] Form language English Hindi Refer the instruction kit for filing the form. I. REGISTRATION AND OTHER DETAILS (i) * Corporate Identification Number (CIN) of the company Pre-fill Global Location Number (GLN) of the company * Permanent Account Number (PAN) of the company (ii) (a) Name of the company (b) Registered office address (c) *e-mail ID of the company (d) *Telephone number with STD code (e) Website (iii) Date of Incorporation (iv) Type of the Company Category of the Company Sub-category of the Company (v) Whether company is having share capital Yes No (vi) *Whether shares listed on recognized Stock Exchange(s) Yes No Page 1 of 17 (a) Details of stock exchanges where shares are listed S. No. Stock Exchange Name Code 1 2 (b) CIN of the Registrar and Transfer Agent Pre-fill Name of the Registrar and Transfer Agent Registered office address of the Registrar and Transfer Agents (vii) *Financial year From date 01/04/2020 (DD/MM/YYYY) To date 31/03/2021 (DD/MM/YYYY) (viii) *Whether Annual general meeting (AGM) held Yes No (a) If yes, date of AGM 27/07/2021 (b) Due date of AGM 30/09/2021 (c) Whether any extension for AGM granted Yes No II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY *Number of business activities 1 S.No Main Description of Main Activity group Business Description of Business Activity % of turnover Activity Activity of the group code Code company C C6 III.
    [Show full text]